Mitoxantrone-Etoposide or HD-ARA-C/Mitoxantrone for Remission Induction in Children with First Relapse of AML

  • K. Stahnke
  • J. Ritter
  • J. Boos
  • U. Creutzig
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 37)

Abstract

One third of children with AML, initially responding to chemotherapy encounter recurrence of their disease. An effective chemotherapeutic regimen with tolerable toxicity is needed for this group of heavily pretreated children. In the past AML-BFM protocols did not specify for a salvage therapy. Reinduction chemotherapy with High Dose Ara-C/Mitoxantrone (HAM) or Mitoxantrone/Etoposide (Mitox/VP) was proposed. We performed a retrospective analysis among patients with first relapse previously treated with the AML-BFM 87 protocol with respect to initial response rates, toxicity and long term survival comparing the different reinduction regimen.

Keywords

Leukemia Cytosine Measle Allo Aspergillosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Miller LP, Pyesmany AF, Wolff LJ, Rogers PCJ, Siegel SE, Wells RJ, Buckley JD, Hammond GD: Successful reinduction therapy with Amsacrine and Cyclocytidine in acute nonlymphoblastic leukemia in children. Cancer (1991) 67: 2235–2240PubMedCrossRefGoogle Scholar
  2. 2.
    Mirro jr. J, Crom WR, Kalwinsky DK, Santane VM, Baker DK, Belt J: Targeted plasma drug concentration: a new therapeutic approach to relapsed nonlymphoblastic leukemia in children. Hematology and Blood Transfusion (1990) 32: 82–86CrossRefGoogle Scholar
  3. 3.
    Movassaghi N, Higgins G, Pyesmany A, Baehner R, Chard R, Sather H, Hammond D Evaluation of Cyclocytidine in reinduction and maintenance therapy of children with acute nonlymphocytic leukemia previously treated with Cytosine Arabinoside: A Report from Children’s Cancer Study Group. Med. Ped. Oncol. (1984) 12:352–356CrossRefGoogle Scholar
  4. 4.
    Stahnke K, Ritter J, Schellong G, Beck JD, Kabisch H, Lampert F, Creutzig U: Rezidivbehandlung bei akuter myeloischer Leukämie im Kindesalter. Klin. Pädiatr. (1992) 204: 253–257PubMedCrossRefGoogle Scholar
  5. 5.
    Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Büchner T: Definition of refractoriness against conventional chemotherapy in acute myelogenous Leukemia: A proposal based on the results of retreatment by Thioguanine, Cytosine Arabinoside, and Daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 4, (1990) 184–188PubMedGoogle Scholar
  6. 6.
    Kantarjian HM, Keatin MJ, Walters RS, McCredie KB, Freireich EJ: The characteristics and outcome of patients with late relapse acute myelogenous leukemia. JCO (1988) 6: 232–238Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • K. Stahnke
    • 1
  • J. Ritter
    • 2
  • J. Boos
    • 2
  • U. Creutzig
    • 2
  1. 1.Abt. Kinderheilkunde IIUniversitäts-Kinderklinik UlmUlmGermany
  2. 2.Universitäts-Kinderklinik MünsterMünsterGermany

Personalised recommendations